Skip to main content
Log in

Prednicarbate Biotransformation in Human Foreskin Keratinocytes and Fibroblasts

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. Evaluation of skin layer-specific prednicarbate (PC) biotransformation, possibly explaining the improved benefit/risk ratio of this topical corticosteroid in atopic dermatitis (1,2).

Methods. Metabolism of PC in keratinocyte and fibroblast monolayers derived from human juvenile foreskin was evaluated. Drug concentration was determined by HPLC/UV-absorption. Accompanying cell viability tests (MTT-tests) were performed to exclude toxic drug effects.

Results. Keratinocytes hydrolyzed the double ester PC (2.5 × 10−6 M) at position 21 to the monoester prednisolone 17-ethylcarbonate (P17EC) which nonenzymatically transformed to prednisolone 21-ethylcarbonate (P21EC). This metabolite was enzymatically cleaved to prednisolone (PD), the main biotransformation product at 24 hours. Fibroblasts, however, showed a distinctively lower enzyme activity. Both, PC and P17EC (or rather P21EC) were hydrolyzed to a minor extent only. The biotransformation pathway, however, was the same. When P17EC was added separately, it transformed to P21EC and again was cleaved by keratinocytes to a much higher extent. Despite of the rather high glucocorticoid concentration MTT-tests proved a non-disturbed cell viability and proliferation rate.

Conclusions. Extrapolating our results to the in-vivo situation, topically applied PC may be metabolized by epidermal cells during skin penetration. A complex mixture of compounds reaches the dermis, whose fibroblasts are barely able to metabolize the steroids. Since skin atrophy is less pronounced with PC as compared to conventional halogenated glucocorticoids, less potent PC metabolites appear to be the dominant species in the dermis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

REFERENCES

  1. H. C. Korting, D. Vieluf, and M. J. Kerscher. Eur. J. Pharmacol. 42:159–61 (1992).

    Google Scholar 

  2. M. J. Kerscher and H. C. Korting. Acta Derm. Venereol. 72:214–16 (1992).

    PubMed  Google Scholar 

  3. D. B. Robertson and H. I. Maibach. In R. P. Schleimer, H. N. Claman, and A. Oronsky (eds.), Anti-inflammatory steroid action, Academic Press, San Diego, 1989, pp. 494–524.

    Google Scholar 

  4. M. Schäfer-Korting, M.-H. Schmid, and H. C. Korting. Drug Safety 14:375–385 (1996).

    PubMed  Google Scholar 

  5. M. Schäfer-Korting and A. Gysler. In H. C. Korting, and M. Schäfer-Korting (eds.), The benefit/risk ratio: A handbook for the rational use of potentially hazardous drugs, CRC Press, Boca Raton, Florida, (in press).

  6. M. Schäfer-Korting, H. C. Korting, M. J. Kerscher, and S. Lenhard. Clin. Pharmacol. Ther. 54:448–456 (1993).

    PubMed  Google Scholar 

  7. M. J. Kerscher and H. C. Korting. Skin Pharmacol. 5:77–80 (1992).

    PubMed  Google Scholar 

  8. A. Aliaga, M. Rodríguez, M. Armijo, J. Bravo, A. López Avila, J. M. Mascaro, J. Ferrando, R. Del Rio, R. Lozano, and A. Balaguer. Int. J. Dermatol. 35:131–132 (1996).

    PubMed  Google Scholar 

  9. H. J. Vogt and T. Höhler. In C. Christophers, E. Schöpf, A. M. Kligman, and R. B. Stoughton (eds.), Topical corticosteroid therapy. A novel approach to safer drugs, Raven Press, New York, 1988, pp. 169–79.

    Google Scholar 

  10. R. Hein, H. C. Korting, and T. Mehring. Skin Pharmacol. 7:300–306 (1994).

    PubMed  Google Scholar 

  11. H. C. Korting, E. Hülsebus, M. Kerscher, R. Greber, and M. Schäfer-Korting. Br. J. Dermatol. 133:54–59 (1995).

    PubMed  Google Scholar 

  12. C. M. Bamberger, A.-M. Bamberger, M. de Castro, and G. P. Chrousos. J. Clin. Invest. 95:2435–41 (1995).

    PubMed  Google Scholar 

  13. J. Barth, K. H. Lehr, H. Derendorf, H. W. Möllmann, Th. Höhler, and G. Hochhaus. Skin Pharmacol. 6:179–186 (1993).

    PubMed  Google Scholar 

  14. K. H. Kim and N. L. Henderson. In E. Christophers, E. Schöpf, A. M. Kligman, and R. B. Stoughton (eds.), Topical corticosteroid therapy. A novel approach to safer drugs, Raven Press, New York, 1988, pp. 49–56.

    Google Scholar 

  15. H.-M. Kellner, H. G. Eckert, H. W. Fehlhaber, I. Hornke, and R. Oekonomopulos. Z. Hautkr. 61:18–40 (1986).

    PubMed  Google Scholar 

  16. G. Würthwein, S. Rehder, and P. Rohdewald. Pharmazeutische Zeitung Wissenschaft 4:161–166 (1992).

    Google Scholar 

  17. M. Pagé, N. Bejaoui, B. Cinq-Mars, and P. Lemieux. Int. J. Immunopharmacol. 10:785–793 (1988).

    PubMed  Google Scholar 

  18. R. D. Carr and R. G. Wieland. Arch. Dermatol. 94:81–84 (1966).

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gysler, A., Lange, K., Korting, H.C. et al. Prednicarbate Biotransformation in Human Foreskin Keratinocytes and Fibroblasts. Pharm Res 14, 793–797 (1997). https://doi.org/10.1023/A:1012162708675

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1012162708675

Navigation